BIIB076 (anti-tau mAb) moving into pre-IND toxicology studies

BIIB076, an anti-tau monoclonal antibody discovered by Neurimmune has entered into the development stage towards IND. Tau is a target that is believed to play a central role in Alzheimer's disease. Biogen acquired Neurimmune’s anti-tau program NI-105 in 2010, together with its anti-alpha-synuclein (BIIB054) program for Parkinson’s disease, which is in Phase 1 clinical trials.